Atrial FibrillationRIBATAFRICA-AFNCT06674304
Registry Initiative Across Borders for Atrial Fibrillation in Africa
An observational study of Atrial Fibrillation and Atrial Fibrillation (Prevention of Stroke), run by Mohammed VI University Hospital at 1 site in Morocco.
Trial summary
Atrial fibrillation is a penalizing disease in several ways: morbidity and mortality, health costs. Several multicenter registries have been published. Until now, no multicenter registry involving several countries has been carried out in Africa. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Atrial Fibrillation, Atrial Fibrillation (Prevention of Stroke), ATRIAL FIBRILLATION, Syncope
- How many people
- 3,000 participants
- Where
- 1 siteMorocco
- Study dates
- 22 Oct 2024to Oct 2025
- How long will I take part?
- 6 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: About 3000 patients will be included in the study according to the following criteria: Inclusion criteria * Patients aged ≥ 18 years old * Patients with a documented history of AF for any length of time before enrolment or AF first diagnosed at enrolment visit/hospitalization * Patients previously diagnosed with AF must have at least one documented visit or hospitalization for AF (or AF-related complications) within the last 12 months before enrolment Exclusion criteria * No formal diagnosis of AF in medical records * Only atrial flutter or other atrial tachycardia diagnosed * Participation in a clinical trial (but participation in another registry is allowed)
Who may be able to join
- Patients aged ≥ 18 years old
- Patients with a documented history of AF for any length of time before enrolment or AF first diagnosed at enrolment visit/hospitalization
- Patients previously diagnosed with AF must have at least one documented visit or hospitalization for AF (or AF-related complications) within the last 12 months before enrolment
Who cannot join
- No formal diagnosis of AF in medical records
- Only atrial flutter or other atrial tachycardia diagnosed
- Participation in a clinical trial (but participation in another registry is allowed)
Trial locations and contacts
1 site in 1 country.
Morocco1 site
Mohammed VI University Hospital of Tangier
Tangier, Tangier, 90000
About this study
Atrial fibrillation is a penalizing disease in several ways: morbidity and mortality, health costs. Several multicenter registries have been published. Until now, no multicenter registry involving several countries has been carried out in Africa. The goal of RIBAT AF Africa is to fill this gap, by recruting patients from twelve african centers. All the centers are a third level Atrial Fibrillation managment facility centers.
After recruitment , a complete clinical assessment with analysis of comorbidities will be a priority of this registry to try to understand the epidemiological profile of atrial fibrillation in Africa. Then, we will proceed to the temporal classification of atrial fibrillation according to the 2024 ESC recommendations (type and thromboembolic risk in particular.).
Read more
After this step, the management will be analyzed with three main axes: management of comorbidities, antithrombotic treatment, rhythm and frequency control. Some therapeutic techniques such as ablation of atrial fibrillation were discussed without much detail because many countries do not yet have access to these expensive techniques.
A six-month evaluation is necessary to judge above all the applicability of the measures accessible in all countries and in particular anticoagulant treatment.
All these data will be recorded anonymously and electronically. Each country can have access to its own data anytime. The statistical analysis will be carried out by a team within the University Hospital of Tangier , as well as all IT logistics. This team will also organize electronic monitoring and underlying all abnomalities in CRF.
Read the detailed description
- Rational
Atrial fibrillation is a penalizing disease in several ways: morbidity and mortality, health costs. Several multicenter registries have been published. Until now, no multicenter registry involving several countries has been carried out. The goal of RIBAT AF Africa is to fill this gap.
II. Study objectives
- To understand the epidemiological profile of atrial fibrillation in Africa,
- to describe the management of atrial fibrillation in Morocco
- to proceed to the temporal classification of atrial fibrillation according to the 2024 ESC recommendations (type and thromboembolic risk in particular.),
- to analyze and describe the management of comorbidities,
- to describe the antithrombotic treatment,
- to study the association between heart failure with preserved ejection fraction and FA
- to analyze the rhythm and frequency control.
- to describe the imaging features in FA
III. Study timeline
A six-month evaluation is necessary to judge above all the applicability of the measures accessible in all countries and in particular anticoagulant treatment. The data collection's start estimation is planned for October 2024. Result will be available in October 2025.
IV. Project description
- Study design This is a multicentric, prospective and observational study, that will be held simultaneously in 13 african countries. The Moroccan center represented by the Mohammed VI university hospital is the coordinating center as well as the principal investigator (PI) center for this study.
- Population About 3000 patients will be included in the study according to the following criteria: Inclusion criteria
- Patients aged ≥ 18 years old
- Patients with a documented history of AF for any length of time before enrolment or AF first diagnosed at enrolment visit/hospitalization
- Patients previously diagnosed with AF must have at least one documented visit or hospitalization for AF (or AF-related complications) within the last 12 months before enrolment Exclusion criteria
- No formal diagnosis of AF in medical records
- Only atrial flutter or other atrial tachycardia diagnosed
- Participation in a clinical trial (but participation in another registry is allowed) For the sampling procedures, all patients who meet the inclusion criteria, and followed for management in the study centers, will be included exhaustively until the needed number of subjects is reached.
- Procedure
- Investigators The 'RIBAT-AFRICA-FA' registry brings together 13 investigating centers in 13 countries; Benin, Cameroun, Egypt, Ethiopia, Gabon, Ivory Coast, Kenya, Mauritania, Morocco, Mali, Niger, Senegal and Tunisia. Each investigating center is located in a university hospital and chaired by a professor of cardiology. In Morocco, the cardiology department of the Mohammed VI University Hospital is the coordinating centre and main investigator. It also coordinates the inclusion of patients in several private cardiology practices in order to ensure that the data is representative of the whole of Morocco.
- Data collection A Case Report Form (CRF) has been developed by the Moroccan Society of Cardiology, and will be used to collect anamnestic, clinical, exploratory and therapeutic data, as well as six-month outcomes (see appendix). For each patient included in this study, the CRF will be completed at inclusion, throughout the initial management period and after six months of treatment.
- Data managment The RIBAT-AFRICA-FA registry will be managed by the Epidemiology and Public Health team and the IT team at CHU Mohammed VI of Tangiers. For data collection, an electronic CRF (eCRF) has been created on the CHU Mohammed VI of Tanger's RedCap application. For each investigating center, a private account was created and communicated. In addition, a training session on the use of the eCRF was organized for all investigators. Throughout the study period, monitoring and data quality management will be carried out by the epidemiology team at CHU Mohammed VI de Tanger. Supervision and coordination of the registry is the responsibility of the Head of Cardiology at Tangier University Hospital.
- Statistical Analysis
Statistical analysis will be performed using IBM SPSS version 25 software. Descriptive data for continuous variables will be presented as means/standard deviation or Median/IQR according to the normality of the distributions, while qualitative variables will be presented as percentages with 95% confidence intervals. Chi-square, Student's t-test or ANOVA will be used within the limits of their respective validity conditions, and where appropriate, non-parametric tests will be used. Multivariate analyses may be indicated, in which case logistic regression and/or the Cox model may be used depending on the model.
- Ethical Considerations
- Funding The project is sponsored by the Moroccan laboratory Afric-Phar, which is facilitating and taking charge of all logistical aspects of project implementation, including coordination between the investigating centers. The sponsor will not have access to the data circuit from collection to statistical analysis and publication.
- Conflit of interest no conflicts of interest to declare.
- Patient's information Patients will have access to a detailed information sheet before their inclusion. Each investigator will explain in a very satisfactory manner the objectives of the study as well as its contribution for improving medical knowledge concerning FA. No additional risk is incurred by the patients included, in particular each patient has the right to refuse participation without this refusal impacting the normal course of the care process.
- Consent information Informed consent Will be obtained from each patient before its inclusion.
- Other ethical considerations The data collected as part of this project will be processed in accordance with all standards of good practice and confidentiality preservation.
The data will be stored on a secure server owned by the University Hospital Center (CHU).
No additional paraclinical investigations will be conducted outside of routine care.
- Conditions
- Atrial Fibrillation, Atrial Fibrillation (Prevention of Stroke), ATRIAL FIBRILLATION, Syncope
- Keywords
- Atrial fibrillation, Registry, Africa, Morocco, antithrombotic treatment
- Medical subject headings
- Atrial Fibrillation, Syncope
What is being measured
The primary outcome is the main question the study is designed to answer.
Arial fibrillation complications under treatment
After inclusion, the investigators carry out a six-month follow-up for the patients. During this prospective follow-up period, the primary judgment criterion that must be documented by the investigators is the occurrence of a complication linked to AF or its medical management. The main complications to be looked for are :
- Death
- Non fatal stroke or systemic embolic event
- Non fatal haemorrhagic event
- Drug side effects
Measured: Six month follow up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Nov 2024
- Study start22 Oct 2024
- Primary completionMay 2025 (estimated)
- Study completionOct 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atrial FibrillationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 3,000 participants (estimated)
- Target duration
- 6 Months
Sponsor and investigators
- Lead sponsor
- Mohammed VI University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, RAISSUNI Zainab, Mohammed VI University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06674304
- Sponsor's protocol ID
- Mohammed VI UH Tangier
- Acronym
- RIBATAFRICA-AF
- Status last verified
- Nov 2024
- First submitted
- 3 Nov 2024
- Last updated
- 6 Nov 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Registry Initiative Across Borders for Atrial Fibrillation in Africa
- ClinicalTrials.gov ID
- NCT06674304
- Acronym / sponsor ID
- RIBATAFRICA-AF / Mohammed VI UH Tangier
- Conditions
- Atrial Fibrillation, Atrial Fibrillation (Prevention of Stroke), ATRIAL FIBRILLATION, Syncope
- Keywords
- Atrial fibrillation, Registry, Africa, Morocco, antithrombotic treatment
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 3,000 participants (estimated)
- Lead sponsor
- Mohammed VI University HospitalUniversity, hospital or other
- Study start
- 22 Oct 2024 (actual)
- Primary completion
- May 2025 (estimated)
- Study completion
- Oct 2025 (estimated)
- First posted
- 5 Nov 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Atrial fibrillation is a penalizing disease in several ways: morbidity and mortality, health costs. Several multicenter registries have been published. Until now, no multicenter registry involving several countries has been carried out in Africa. The goal of RIBAT AF Africa is to fill this gap, by recruting patients from twelve african centers. All the centers are a third level Atrial Fibrillation managment facility centers.
After recruitment , a complete clinical assessment with analysis of comorbidities will be a priority of this registry to try to understand the epidemiological profile of atrial fibrillation in Africa. Then, we will proceed to the temporal classification of atrial fibrillation according to the 2024 ESC recommendations (type and thromboembolic risk in particular.).
After this step, the management will be analyzed with three main axes: management of comorbidities, antithrombotic treatment, rhythm and frequency control. Some therapeutic techniques such as ablation of atrial fibrillation were discussed without much detail because many countries do not yet have access to these expensive techniques.
A six-month evaluation is necessary to judge above all the applicability of the measures accessible in all countries and in particular anticoagulant treatment.
All these data will be recorded anonymously and electronically. Each country can have access to its own data anytime. The statistical analysis will be carried out by a team within the University Hospital of Tangier , as well as all IT logistics. This team will also organize electronic monitoring and underlying all abnomalities in CRF.
Detailed description
- Rational
Atrial fibrillation is a penalizing disease in several ways: morbidity and mortality, health costs. Several multicenter registries have been published. Until now, no multicenter registry involving several countries has been carried out. The goal of RIBAT AF Africa is to fill this gap.
II. Study objectives
- To understand the epidemiological profile of atrial fibrillation in Africa,
- to describe the management of atrial fibrillation in Morocco
- to proceed to the temporal classification of atrial fibrillation according to the 2024 ESC recommendations (type and thromboembolic risk in particular.),
- to analyze and describe the management of comorbidities,
- to describe the antithrombotic treatment,
- to study the association between heart failure with preserved ejection fraction and FA
- to analyze the rhythm and frequency control.
- to describe the imaging features in FA
III. Study timeline
A six-month evaluation is necessary to judge above all the applicability of the measures accessible in all countries and in particular anticoagulant treatment. The data collection's start estimation is planned for October 2024. Result will be available in October 2025.
IV. Project description
- Study design This is a multicentric, prospective and observational study, that will be held simultaneously in 13 african countries. The Moroccan center represented by the Mohammed VI university hospital is the coordinating center as well as the principal investigator (PI) center for this study.
- Population About 3000 patients will be included in the study according to the following criteria: Inclusion criteria
- Patients aged ≥ 18 years old
- Patients with a documented history of AF for any length of time before enrolment or AF first diagnosed at enrolment visit/hospitalization
- Patients previously diagnosed with AF must have at least one documented visit or hospitalization for AF (or AF-related complications) within the last 12 months before enrolment Exclusion criteria
- No formal diagnosis of AF in medical records
- Only atrial flutter or other atrial tachycardia diagnosed
- Participation in a clinical trial (but participation in another registry is allowed) For the sampling procedures, all patients who meet the inclusion criteria, and followed for management in the study centers, will be included exhaustively until the needed number of subjects is reached.
- Procedure
- Investigators The 'RIBAT-AFRICA-FA' registry brings together 13 investigating centers in 13 countries; Benin, Cameroun, Egypt, Ethiopia, Gabon, Ivory Coast, Kenya, Mauritania, Morocco, Mali, Niger, Senegal and Tunisia. Each investigating center is located in a university hospital and chaired by a professor of cardiology. In Morocco, the cardiology department of the Mohammed VI University Hospital is the coordinating centre and main investigator. It also coordinates the inclusion of patients in several private cardiology practices in order to ensure that the data is representative of the whole of Morocco.
- Data collection A Case Report Form (CRF) has been developed by the Moroccan Society of Cardiology, and will be used to collect anamnestic, clinical, exploratory and therapeutic data, as well as six-month outcomes (see appendix). For each patient included in this study, the CRF will be completed at inclusion, throughout the initial management period and after six months of treatment.
- Data managment The RIBAT-AFRICA-FA registry will be managed by the Epidemiology and Public Health team and the IT team at CHU Mohammed VI of Tangiers. For data collection, an electronic CRF (eCRF) has been created on the CHU Mohammed VI of Tanger's RedCap application. For each investigating center, a private account was created and communicated. In addition, a training session on the use of the eCRF was organized for all investigators. Throughout the study period, monitoring and data quality management will be carried out by the epidemiology team at CHU Mohammed VI de Tanger. Supervision and coordination of the registry is the responsibility of the Head of Cardiology at Tangier University Hospital.
- Statistical Analysis
Statistical analysis will be performed using IBM SPSS version 25 software. Descriptive data for continuous variables will be presented as means/standard deviation or Median/IQR according to the normality of the distributions, while qualitative variables will be presented as percentages with 95% confidence intervals. Chi-square, Student's t-test or ANOVA will be used within the limits of their respective validity conditions, and where appropriate, non-parametric tests will be used. Multivariate analyses may be indicated, in which case logistic regression and/or the Cox model may be used depending on the model.
- Ethical Considerations
- Funding The project is sponsored by the Moroccan laboratory Afric-Phar, which is facilitating and taking charge of all logistical aspects of project implementation, including coordination between the investigating centers. The sponsor will not have access to the data circuit from collection to statistical analysis and publication.
- Conflit of interest no conflicts of interest to declare.
- Patient's information Patients will have access to a detailed information sheet before their inclusion. Each investigator will explain in a very satisfactory manner the objectives of the study as well as its contribution for improving medical knowledge concerning FA. No additional risk is incurred by the patients included, in particular each patient has the right to refuse participation without this refusal impacting the normal course of the care process.
- Consent information Informed consent Will be obtained from each patient before its inclusion.
- Other ethical considerations The data collected as part of this project will be processed in accordance with all standards of good practice and confidentiality preservation.
The data will be stored on a secure server owned by the University Hospital Center (CHU).
No additional paraclinical investigations will be conducted outside of routine care.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 6 Months
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- About 3000 patients will be included in the study according to the following criteria: Inclusion criteria * Patients aged ≥ 18 years old * Patients with a documented history of AF for any length of time before enrolment or AF first diagnosed at enrolment visit/hospitalization * Patients previously diagnosed with AF must have at least one documented visit or hospitalization for AF (or AF-related complications) within the last 12 months before enrolment Exclusion criteria * No formal diagnosis of AF in medical records * Only atrial flutter or other atrial tachycardia diagnosed * Participation in a clinical trial (but participation in another registry is allowed)
Key inclusion criteria (3 listed)
- Patients aged ≥ 18 years old
- Patients with a documented history of AF for any length of time before enrolment or AF first diagnosed at enrolment visit/hospitalization
- Patients previously diagnosed with AF must have at least one documented visit or hospitalization for AF (or AF-related complications) within the last 12 months before enrolment
Key exclusion criteria (3 listed)
- No formal diagnosis of AF in medical records
- Only atrial flutter or other atrial tachycardia diagnosed
- Participation in a clinical trial (but participation in another registry is allowed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Arial fibrillation complications under treatment
Time frame: Six month follow up
After inclusion, the investigators carry out a six-month follow-up for the patients. During this prospective follow-up period, the primary judgment criterion that must be documented by the investigators is the occurrence of a complication linked to AF or its medical management. The main complications to be looked for are : 1. Death 2. Non fatal stroke or systemic embolic event 3. Non fatal haemorrhagic event 4. Drug side effects
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2024.
- Individual participant dataSharing planned: Undecided
Related trials for Atrial Fibrillation
Active, not recruiting
Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)
Paroxysmal AF
Active, not recruitingObservational study
Concomitant Left Atrial Appendage Closure and Pulsed Field Ablation-Asia
Concomitant Procedures, Atrial Fibrillation
Active, not recruiting
CONVERGE Post-Approval Study (PAS)
Chronic Atrial Fibrillation
Recruiting
Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy
Ischemic Stroke, Atrial Fibrillation
RecruitingPhase 2
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Atrial Fibrillation (AF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Atrial Fibrillation and Atrial Fibrillation (Prevention of Stroke), run by Mohammed VI University Hospital at 1 site in Morocco.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 6 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Morocco. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Arial fibrillation complications under treatment (time frame: Six month follow up). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2024.